Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Exp Parasitol ; 208: 107801, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31730781

RESUMEN

Taenia solium is a parasite whose larvae (cysticerci) can locate in the central nervous system of humans and cause neurocysticercosis (NC). The introduction of cysticidal drugs such as albendazole (ABZ) for the treatment of NC has significantly improved its prognosis. However, treatment is not always effective, and the high levels of corticosteroids used to prevent inflammatory complications in this disease could be, partly, the cause of this observation. In this context, this study investigated, using the experimental mouse model of intraperitoneal infection with Taenia crassiceps, the influence of corticosteroid administration on the therapeutic efficacy of ABZ. We evaluated and compared the effects of ABZ, dexamethasone (DXM) and their combination (ABZ + DXM) on cyst viability, both in vitro and in vivo. Serum levels of IL-4, IFN-gamma, IL-6 and IL-10 were evaluated in the in vivo study. Results showed that the treatment with ABZ, in vitro and in vivo, was associated with a high number of parasites deaths. Concomitant treatment with DXM did not alter ABZ in vitro cysticidal activity but reduced its effectiveness significantly in the in vivo experimental model. Cytokine serum levels did not change significantly in treated mice compared to the controls. The results of this study are relevant as they indicate a negative effect of corticosteroids on the efficacy of cysticidal therapy. In human neurocysticercosis, control of inflammation is of great importance to most patients in order to avoid complications. Corticosteroids are generally used for this purpose and the results of this study demonstrate the need to find other therapeutic strategies. Further studies are needed to better understand the mechanisms involved.


Asunto(s)
Albendazol/farmacología , Antihelmínticos/farmacología , Antiinflamatorios/farmacología , Cisticercosis/tratamiento farmacológico , Dexametasona/farmacología , Taenia/efectos de los fármacos , Albendazol/uso terapéutico , Animales , Antihelmínticos/uso terapéutico , Antiinflamatorios/uso terapéutico , Dexametasona/uso terapéutico , Interacciones Farmacológicas , Ensayo de Inmunoadsorción Enzimática , Femenino , Interferón gamma/sangre , Interleucina-10/sangre , Interleucina-4/sangre , Interleucina-6/sangre , Ratones , Ratones Endogámicos BALB C
2.
Exp Parasitol ; 149: 1-6, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25500213

RESUMEN

In the search of new alternatives for neurocysticercosis treatment, Taenia crassiceps ORF strain cysticerci have been used instead of T. solium for in vitro studies. Up to date, the main criteria for the use of the murine cysticercosis model for drug efficacy evaluation have not been assessed. The aim of the present study was to evaluate the influence of two of the main variables related to the in vivo efficacy: the length of drug treatment and the starting time of treatment after experimental infection, using albendazole (ABZ) and praziquantel (PZQ) as test drugs. Additionally, the relationship between the number of cysts and the parasite weight was assessed. For the study, female BALB/c mice were experimentally infected with T. crassiceps cysts. Three different post-infection periods (10, 20 and 30 days) and three different lengths of treatment with ABZ or PZQ (10, 20 and 30 days) were selected. The efficacy of each treatment was evaluated by comparison with a control group. Our results show that for in vivo efficacy studies, the best time to start the drug treatment is 10 days post-infection and that a minimum of 20 days of treatment is required when ABZ or PZQ are used as positive control. Moreover, in this model the parasite weight can be used as a rapid tool to measure the in vivo drug activity.


Asunto(s)
Albendazol/uso terapéutico , Antihelmínticos/uso terapéutico , Cisticercosis/tratamiento farmacológico , Praziquantel/uso terapéutico , Albendazol/administración & dosificación , Animales , Antihelmínticos/administración & dosificación , Cisticercosis/parasitología , Cysticercus/efectos de los fármacos , Modelos Animales de Enfermedad , Esquema de Medicación , Evaluación Preclínica de Medicamentos , Femenino , Ratones , Ratones Endogámicos BALB C , Praziquantel/administración & dosificación , Factores de Tiempo
3.
Exp Parasitol ; 156: 79-86, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26072200

RESUMEN

In the search of new alternatives for neurocysticercosis treatment, the cysticidal activity of organic extracts of Teloxys graveolens was evaluated. The in vitro activity of hexane, ethyl acetate and methanol extracts against Taenia crassiceps cysts was tested and the selectivity index relative to human fibroblasts was determined. Subsequently, the in vivo efficacy of the methanolic extract at doses of 200 and 500 mg/kg in the murine cysticercosis model was evaluated. The ultrastructural effects in vitro and in vivo of the methanolic extract were also investigated using scanning electron microscopy. Additionally, a bioassay-guided fractionation for the isolation of the cysticidal components was performed. Our in vitro findings revealed that all extracts exhibited good cysticidal activity with EC50 values from 44.8 to 67.1 µg/mL. Although the ethyl acetate and methanolic extracts displayed low cytotoxicity, the methanolic extract was the most selective. The methanolic extract also showed in vivo efficacy which was similar to that obtained with ABZ. Significant alterations were found on the germinal layer of the cysts, with a high accumulation of granules of glycogen and vacuoles. The bioguided fractionation of methanolic extract led to the isolation of three flavonoids: chrysin, pinocembrin and pinostrobin; among them, pinocembrin was the compound that displayed cysticidal activity. This is the first study which reveals that T. graveolens could be a potential source for cysticidal and non-toxic compounds.


Asunto(s)
Amaranthaceae/química , Cisticercosis/tratamiento farmacológico , Cysticercus/efectos de los fármacos , Extractos Vegetales/farmacología , Animales , Bioensayo , Cysticercus/ultraestructura , Femenino , Fibroblastos/efectos de los fármacos , Flavanonas/química , Flavanonas/aislamiento & purificación , Flavanonas/farmacología , Flavonoides/química , Flavonoides/aislamiento & purificación , Flavonoides/farmacología , Encía/citología , Humanos , Ratones , Ratones Endogámicos BALB C , Microscopía Electrónica de Transmisión , Componentes Aéreos de las Plantas/química , Extractos Vegetales/química , Extractos Vegetales/uso terapéutico , Extractos Vegetales/toxicidad
4.
Neurotox Res ; 31(4): 532-544, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28092019

RESUMEN

Several physiological events in the brain are regulated by the endocannabinoid system (ECS). While synthetic cannabinoid receptor (CBr) agonists such as WIN55,212-2 act directly on CBr, agents like URB597, a fatty acid amide hydrolase (FAAH) inhibitor, induce a more "physiological" activation of CBr by increasing the endogenous levels of the endocannabinoid anandamide (AEA). Herein, we compared the pre- and post-treatment efficacy of URB597 and WIN55,212-2 on different endpoints evaluated in the toxic model produced by the mitochondrial toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. MPTP (40 mg/kg, s.c., single injection) decreased locomotor activity, depleted the striatal and nigral levels of dopamine (DA), augmented the levels of lipid peroxidation and protein carbonylation in both regions, decreased the striatal protein levels of tyrosine hydroxylase, and increased the striatal protein content of the subunit 1 (NR1) of the N-methyl-D-aspartate receptor (NMDAr). Both URB597 (0.3 mg/kg, i.p., once a day) and WIN55,212-2 (10 µg/kg, i.p., twice a day), administered for five consecutive days, either before or after the MPTP injection, prevented the alterations elicited by MPTP and downregulated NMDAr. Our results support a modulatory role of the ECS on the toxic profile exerted by MPTP in mice via the stimulation of antioxidant activity and the induction of NMDAr downregulation and hypofunction, and favor the stimulation of CBr as an effective experimental therapeutic strategy.


Asunto(s)
Benzamidas/farmacología , Benzoxazinas/farmacología , Carbamatos/farmacología , Dopamina/metabolismo , Locomoción/efectos de los fármacos , Intoxicación por MPTP/metabolismo , Morfolinas/farmacología , Naftalenos/farmacología , Receptores de N-Metil-D-Aspartato/metabolismo , Animales , Cuerpo Estriado/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Intoxicación por MPTP/prevención & control , Masculino , Ratones , Oxidación-Reducción/efectos de los fármacos , Carbonilación Proteica/efectos de los fármacos , Sustancia Negra/metabolismo , Tirosina 3-Monooxigenasa/metabolismo
5.
Acta Trop ; 170: 1-7, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28216368

RESUMEN

Currently, neurocysticercosis treatment involves two drugs: albendazole and praziquantel; however, their efficacy is suboptimal and new cysticidal drugs are needed. The present paper reports the cysticidal activity of extracts of the bark from Prunus serotina against Taenia crassiceps cysts and the isolation and identification of the main components of the most active extract. Results showed that all extracts displayed in vitro cysticidal activity (EC50=17.9-88.5µg/mL), being the methanolic the most active and selective. Also, methanolic extract exhibited in vivo efficacy at 300mg/kg which was similar to that obtained with albendazole. Bio-guided fractionation of methanolic extract led the isolation of 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one (naringenin, NGN), 3,4,5-trimethoxybenzoic acid and 1,3,5-trimethoxybenzene. NGN exhibited in vitro activity, in a time-concentration-dependent manner (EC50=89.3µM]. Furthermore, NGN at a dose of 376.1µmol/kg displayed similar in vivo efficacy than those obtained with albendazole at 188.4µmol/kg. NGN also caused a high level of damage in all parasite tissue in a similar manner than that observed with the methanolic extract. This study represents the first report of the cysticidal properties of the bark of P. serotina. NGN was identified as the main active compound of this specie and other studies are required to explore the potential of this flavanone as cysticidal agent.


Asunto(s)
Antihelmínticos/farmacología , Cisticercosis/tratamiento farmacológico , Flavanonas/farmacología , Extractos Vegetales/farmacología , Prunus avium , Taenia/efectos de los fármacos , Albendazol/farmacología , Animales , Femenino , Ratones , Ratones Endogámicos BALB C
6.
Eur J Med Chem ; 44(4): 1794-800, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18582991

RESUMEN

Despite albendazole being the drug of choice in neurocysticercosis treatment, its low solubility limits its bioavailability; therefore, more research is required in order to find new molecules with cestocidal activity and adequate aqueous solubility. A set of 13 benzimidazole derivatives were synthesized and their in vitro activities were evaluated against Taenia crassiceps cysts, using albendazole sulfoxide as reference molecule, showing that two of them exhibited good activity. Molecular modelling revealed that the cysticidal efficacy depends on the presence on the molecule of an H in the 1-position, a planar carbamate group at 2-position, and if the substituent in 5-position is voluminous, it should be orthogonal to the benzimidazole ring.


Asunto(s)
Antihelmínticos/química , Antihelmínticos/farmacología , Bencimidazoles/química , Bencimidazoles/farmacología , Diseño de Fármacos , Taenia/efectos de los fármacos , Albendazol/análogos & derivados , Albendazol/farmacología , Animales , Antihelmínticos/síntesis química , Bencimidazoles/síntesis química , Modelos Moleculares , Estándares de Referencia
7.
Transl Res ; 152(1): 31-7, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18593635

RESUMEN

Local diminution of the neural growth factor (NGF) contributes to the apparition of diabetic neuropathy. All-trans retinoic acid (RA) increases the expression of neural growth factor and its receptor participating in translation pathways. This study evaluates RA as a treatment of diabetic neuropathy: 120 mice were assigned randomly to 4 groups. Group A (n = 30) was taken as control; group B (n = 30) received 50 mg/kg intraperitoneal streptozotocin (STZ); group C (n = 30) received STZ, and after diabetic neuropathy developed, they were treated with subcutaneous RA 20 mg/kg daily during 60 days; and group D (n = 30) only received RA. Plasma glucose, thermosensitive tests, serum, and the nerve contents of NGF were measured in all animals. Evaluation by electron microscopy was performed in search of morphologic changes secondary to neuropathy and nerve regeneration. Diabetic mice had an increased threshold to pain. Treatment with RA in diabetic mice reverted changes in sensitivity as compared with diabetic mice that received placebo (P < 0.001). No differences in pain threshold among controls, RA, and diabetes mellitus (DM) + RA groups were found. Glucose levels were not affected by the treatment with RA. NGF diminished significantly in the sciatic nerve in diabetic mice as compared with controls and with the RA group. Animals with DM + RA had a significant increase of NGF in nerves as compared with the other groups. RA also regressed the ultrastructural changes induced by diabetes that showed increased neural regeneration. RA can revert functional and ultrastructural changes and induce neural regeneration after the establishment of diabetic neuropathy, possibly because of the increased of NGF concentrations in nerve terminals.


Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Neuropatías Diabéticas/prevención & control , Factor de Crecimiento Nervioso/metabolismo , Regeneración Nerviosa/efectos de los fármacos , Tretinoina/farmacología , Animales , Glucemia/análisis , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/patología , Neuropatías Diabéticas/metabolismo , Neuropatías Diabéticas/patología , Evaluación Preclínica de Medicamentos , Masculino , Ratones , Factor de Crecimiento Nervioso/sangre , Distribución Aleatoria , Nervio Ciático/efectos de los fármacos , Nervio Ciático/metabolismo , Nervio Ciático/ultraestructura , Tretinoina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA